Manzoni Claudia, Mamais Adamantios, Dihanich Sybille, Abeti Rosella, Soutar Marc P M, Plun-Favreau Helene, Giunti Paola, Tooze Sharon A, Bandopadhyay Rina, Lewis Patrick A
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK; Reta Lila Weston Institute and Queen Square Brain Bank, UCL Institute of Neurology, 1 Wakefield Street, London, WC1N 1PJ, UK.
Biochim Biophys Acta. 2013 Dec;1833(12):2900-2910. doi: 10.1016/j.bbamcr.2013.07.020. Epub 2013 Aug 1.
Leucine Rich Repeat Kinase 2 (LRRK2) is one of the most important genetic contributors to Parkinson's disease. LRRK2 has been implicated in a number of cellular processes, including macroautophagy. To test whether LRRK2 has a role in regulating autophagy, a specific inhibitor of the kinase activity of LRRK2 was applied to human neuroglioma cells and downstream readouts of autophagy examined. The resulting data demonstrate that inhibition of LRRK2 kinase activity stimulates macroautophagy in the absence of any alteration in the translational targets of mTORC1, suggesting that LRRK2 regulates autophagic vesicle formation independent of canonical mTORC1 signaling. This study represents the first pharmacological dissection of the role LRRK2 plays in the autophagy/lysosomal pathway, emphasizing the importance of this pathway as a marker for LRRK2 physiological function. Moreover it highlights the need to dissect autophagy and lysosomal activities in the context of LRRK2 related pathologies with the final aim of understanding their aetiology and identifying specific targets for disease modifying therapies in patients.
富含亮氨酸重复激酶2(LRRK2)是帕金森病最重要的遗传因素之一。LRRK2参与了包括巨自噬在内的许多细胞过程。为了测试LRRK2在调节自噬中是否起作用,将LRRK2激酶活性的特异性抑制剂应用于人类神经胶质瘤细胞,并检测自噬的下游读数。所得数据表明,在mTORC1的翻译靶点没有任何改变的情况下,抑制LRRK2激酶活性会刺激巨自噬,这表明LRRK2独立于经典的mTORC1信号传导调节自噬小泡的形成。这项研究首次对LRRK2在自噬/溶酶体途径中的作用进行了药理学剖析,强调了该途径作为LRRK2生理功能标志物的重要性。此外,它强调了在LRRK2相关病理情况下剖析自噬和溶酶体活性的必要性,最终目的是了解其病因并确定针对患者疾病修饰疗法的特定靶点。